Clinical Trial Search – COPD – CPL (US) [Ages 40-75]

This Phase 3 study evaluates the safety and efficacy of an investigational injectable add-on treatment for Chronic Obstructive Pulmonary Disease (COPD).

Converts on completed pre-screener lead

Targeting: The study is strictly limited to the specific locations found in the Live Geos Report. The target audience is adults aged 40 to 75 who have been diagnosed with COPD for at least 12 months and currently use at least one daily maintenance inhaler.

Restrictions: ALL COPY AND CREATIVE must be submitted for compliance approval before going live. The most significant disqualifier for this study is current smoking status; participants must be former smokers who have not smoked for at least 3 months and have a history of at least 10 pack-years. Additionally, candidates must not have an Asthma diagnosis and cannot be on oxygen therapy for more than 12 hours per day.